Lantheus Holdings, Inc. (NASDAQ:LNTH) Given Consensus Rating of “Moderate Buy” by Analysts

Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) have earned an average recommendation of “Moderate Buy” from the nine brokerages that are currently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a hold recommendation and eight have given a buy recommendation to the company. The average twelve-month price target among brokerages that have issued a report on the stock in the last year is $126.00.

A number of equities analysts have commented on the stock. JMP Securities cut their price target on shares of Lantheus from $130.00 to $125.00 and set a “market outperform” rating for the company in a research note on Thursday, August 1st. Leerink Partners increased their target price on Lantheus from $106.00 to $127.00 and gave the company an “outperform” rating in a research note on Thursday, July 11th. Redburn Atlantic initiated coverage on Lantheus in a research note on Tuesday, September 3rd. They set a “buy” rating and a $175.00 price target for the company. Truist Financial cut their price objective on Lantheus from $141.00 to $135.00 and set a “buy” rating for the company in a report on Thursday, August 1st. Finally, B. Riley boosted their target price on Lantheus from $105.00 to $146.00 and gave the stock a “buy” rating in a research report on Thursday, July 25th.

Insiders Place Their Bets

In other news, Director Gary J. Pruden sold 12,530 shares of the stock in a transaction that occurred on Wednesday, July 10th. The stock was sold at an average price of $95.04, for a total transaction of $1,190,851.20. Following the completion of the sale, the director now owns 11,978 shares of the company’s stock, valued at $1,138,389.12. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In other news, Director Gary J. Pruden sold 12,530 shares of the company’s stock in a transaction dated Wednesday, July 10th. The shares were sold at an average price of $95.04, for a total transaction of $1,190,851.20. Following the completion of the transaction, the director now directly owns 11,978 shares of the company’s stock, valued at $1,138,389.12. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CAO Andrea Sabens sold 341 shares of the stock in a transaction dated Monday, July 15th. The stock was sold at an average price of $123.15, for a total transaction of $41,994.15. Following the sale, the chief accounting officer now owns 62,216 shares of the company’s stock, valued at $7,661,900.40. The disclosure for this sale can be found here. Insiders have sold 40,852 shares of company stock valued at $3,922,001 in the last ninety days. Company insiders own 1.50% of the company’s stock.

Hedge Funds Weigh In On Lantheus

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. International Assets Investment Management LLC bought a new position in Lantheus in the 4th quarter worth $407,000. M&T Bank Corp bought a new position in Lantheus in the fourth quarter worth about $320,000. Charles Schwab Investment Management Inc. lifted its holdings in Lantheus by 0.9% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 839,957 shares of the medical equipment provider’s stock worth $52,077,000 after buying an additional 7,590 shares during the period. Principal Securities Inc. bought a new stake in Lantheus during the 4th quarter valued at approximately $28,000. Finally, Qsemble Capital Management LP purchased a new position in shares of Lantheus during the 4th quarter worth approximately $210,000. Institutional investors own 99.06% of the company’s stock.

Lantheus Stock Down 1.8 %

LNTH opened at $105.54 on Wednesday. The company has a debt-to-equity ratio of 0.55, a current ratio of 4.68 and a quick ratio of 4.41. Lantheus has a one year low of $50.20 and a one year high of $126.89. The firm has a market capitalization of $7.32 billion, a P/E ratio of 16.11 and a beta of 0.50. The company has a fifty day moving average price of $105.48 and a 200-day moving average price of $83.15.

Lantheus (NASDAQ:LNTH) last released its quarterly earnings results on Wednesday, July 31st. The medical equipment provider reported $1.61 earnings per share for the quarter, missing the consensus estimate of $1.68 by ($0.07). Lantheus had a net margin of 29.80% and a return on equity of 48.36%. The business had revenue of $394.10 million during the quarter, compared to analysts’ expectations of $382.12 million. During the same period in the previous year, the business earned $1.40 EPS. The business’s revenue was up 22.5% on a year-over-year basis. Equities research analysts expect that Lantheus will post 5.99 earnings per share for the current fiscal year.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.